Aptorum Group Limited announced that its subsidiary company, Aptorum Innovations Holding Limited (“Aptorum Innovations”), has commenced clinical validation of its molecular based rapid pathogen diagnostics liquid biopsy technology (“RPIDD”) for the diagnosis of pathogens including viruses, bacteria, fungi and parasites. Aptorum Innovations announce that under ongoing planned clinical validations in Singapore for RPIDD, 12 patients have been enrolled with febrile neutropenia and sepsis conditions and that over 53 samples have been collected and analyzed. So far, various bacteria and viruses have been detected in these patient samples, including Escherichia coli, Klebsiella pneumoniae and Herpesviridae.

The data have been cross-validated by standard of care diagnostics results such as blood culture technology. RPIDD achieved analytical sensitivity and specificity of spiked samples of at most 100% and 90% respectively at both low depth (60,000 reads) and high depth (1 million reads) sequencing. RPIDD will continue to undergo validations during 2022, in parallel with its pre-commercialization process in 2022.